Department of Pharmacy, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, United States.
Int Immunopharmacol. 2011 Nov;11(11):1663-7. doi: 10.1016/j.intimp.2011.07.024. Epub 2011 Aug 16.
Intravenous immunoglobulin (IVIG) is an immunomodulating agent that induces beneficial therapeutic responses in children and adults. IVIG is not only used for prophylaxis and therapy of infections in patients with primary and secondary immunodeficiencies associated with defective antibody production, but also used for treatment of patients with systemic inflammatory disorders, autoimmune diseases, and neuroimmunologic conditions. IVIG is generally considered a safe and efficacious therapeutic modality. However, it is associated with certain adverse effects including hematologic complications such as hemolytic anemia, leukopenia, neutropenia, monocytopenia, disseminated intravascular coagulation, and changes in blood rheology. Venous and arterial thrombotic complications can also occur following treatment with IVIG in high risk patients. It is very important for clinicians to have the knowledge of those adverse events profiles; and this article summarizes hematologic toxicities associated with IVIG therapy reported in the literature; and describes strategies for their identification and management.
静脉注射免疫球蛋白（IVIG）是一种免疫调节剂，可诱导儿童和成人产生有益的治疗反应。IVIG 不仅用于与抗体产生缺陷相关的原发性和继发性免疫缺陷患者的感染预防和治疗，也用于治疗全身性炎症性疾病、自身免疫性疾病和神经免疫性疾病的患者。IVIG 通常被认为是一种安全有效的治疗方式。然而，它与某些不良反应相关，包括血液学并发症，如溶血性贫血、白细胞减少、中性粒细胞减少、单核细胞减少、弥漫性血管内凝血和血液流变学改变。在高危患者中，使用 IVIG 治疗后也可能发生静脉和动脉血栓并发症。临床医生了解这些不良反应的特征非常重要；本文总结了文献中报道的与 IVIG 治疗相关的血液学毒性，并描述了识别和管理这些毒性的策略。
